董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Roy D. Baynes | 男 | Independent Director | 71 | 32.59万美元 | 4.22 | 2026-07-10 |
| Tien Li Lee | 男 | Director,Chairperson of the Board and Chief Executive Officer | 51 | 606.67万美元 | 319.82 | 2026-07-10 |
| Jeffrey Chi | 男 | Lead Independent Director | 57 | 60.89万美元 | 2.35 | 2026-07-10 |
| Victor Tong, Jr. | 男 | Independent Director | 42 | 58.89万美元 | 2.35 | 2026-07-10 |
| Susan E. Graf | 女 | Independent Director | 53 | 33.91万美元 | 4.34 | 2026-07-10 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Tien Li Lee | 男 | Director,Chairperson of the Board and Chief Executive Officer | 51 | 606.67万美元 | 319.82 | 2026-07-10 |
| Manasi Jaiman | 女 | Chief Medical Officer | 45 | 187.01万美元 | 12.38 | 2026-07-10 |
| Nelson Sun | 男 | Chief Financial Officer and Chief Operating Officer | 49 | 254.79万美元 | 53.85 | 2026-07-10 |
董事简历
中英对照 | 中文 | 英文- Roy D. Baynes
-
RoyD.Baynes，医学博士，博士，自2016年6月起担任公司董事。他曾一直担任Merck Research Laboratories（Merck and Co.，Inc.的研究部门）的高级副总裁兼全球临床开发主管（2013年12月以来），以及Merck and Co.（全球梦百合公司）的首席医疗官（2016年7月以来）。在默克公司任职之前，贝恩斯博士于2012年1月至2013年12月担任生物制药公司吉利德科学公司肿瘤学、炎症和呼吸疗法高级副总裁。在加入Gilead之前，Baynes博士从2002年8月到2012年1月在安进公司（一家生物技术公司）担任越来越重要的职位，最近的职位是担任全球临床开发和治疗领域Vice President血液学/肿瘤学主管。在加入Amgen之前，Baynes博士是韦恩州立大学芭芭拉·安·卡马诺斯癌症研究所（Barbara Ann Karmanos Cancer Institute）的查尔斯·马丁癌症研究教授，该研究所是国家癌症研究所指定的综合癌症中心。Baynes博士撰写了150多篇出版物，是多个国际医学协会的成员或研究员。Baynes博士在南非威特沃特斯兰德大学（University of the Witwatersrand）获得医学学位和哲学博士学位，并在约翰内斯堡医院（Johannesburg Hospital）血液科和肿瘤科完成医学培训。
Roy D. Baynes has served as a member of Board since December 2024. Since July 2022, Dr. Baynes has served as Executive Vice President and Chief Medical Officer of Eikon Therapeutics, Inc. (Nasdaq: EIKN), a biotechnology company. Prior to Eikon Therapeutics, Inc., until April 2022, he served as Senior Vice President and Head of Global Clinical Development at Merck Research Laboratories, the research division of Merck and Co., Inc., commencing in December 2013, and as Chief Medical Officer of Merck and Co., Inc., a global healthcare company, commencing in July 2016. Prior to his roles at Merck and Co., Inc., Dr. Baynes served as Senior Vice President of Oncology, Inflammation and Respiratory Therapeutics at Gilead Sciences, Inc., a biopharmaceutical company, from January 2012 to December 2013. Prior to Gilead Sciences, Inc., Dr. Baynes held positions of increasing responsibility at Amgen Inc., a biotechnology company, including Vice President of Global Clinical Development and Therapeutic Area Head for Hematology/Oncology. Before joining Amgen Inc., Dr. Baynes was the Charles Martin Professor of Cancer Research at the Barbara Ann Karmanos Cancer Institute, a National Cancer Institute designated Comprehensive Cancer Center, at Wayne State University. Dr. Baynes has authored more than 150 publications and is a member or fellow of several international medical societies. Dr. Baynes has served on the Boards of Directors of Natera, Inc. (Nasdaq: NTRA), a genetic testing and diagnostics company, since July 2018; Travere Therapeutics Inc. (formerly known as Retrophin, Inc.) (Nasdaq: TVTX), a biopharmaceutical company, since July 2016; CatalYm GmbH, a privately held Germany based biotechnology company, since January 2024; Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company, since March 2025; and Adcendo ApS, a privately held Danish based antibody drug conjugate company, since February 2025. Previously, from September 2018 to December 2022, he served on the board of directors of Atara Biotherapeutics, Inc., a T cell immunotherapy company. Dr. Baynes received his medical degree and doctorate in philosophy from the University of the Witwatersrand in South Africa, and completed his medical training in the Department of Hematology and Oncology at Johannesburg Hospital. - RoyD.Baynes，医学博士，博士，自2016年6月起担任公司董事。他曾一直担任Merck Research Laboratories（Merck and Co.，Inc.的研究部门）的高级副总裁兼全球临床开发主管（2013年12月以来），以及Merck and Co.（全球梦百合公司）的首席医疗官（2016年7月以来）。在默克公司任职之前，贝恩斯博士于2012年1月至2013年12月担任生物制药公司吉利德科学公司肿瘤学、炎症和呼吸疗法高级副总裁。在加入Gilead之前，Baynes博士从2002年8月到2012年1月在安进公司（一家生物技术公司）担任越来越重要的职位，最近的职位是担任全球临床开发和治疗领域Vice President血液学/肿瘤学主管。在加入Amgen之前，Baynes博士是韦恩州立大学芭芭拉·安·卡马诺斯癌症研究所（Barbara Ann Karmanos Cancer Institute）的查尔斯·马丁癌症研究教授，该研究所是国家癌症研究所指定的综合癌症中心。Baynes博士撰写了150多篇出版物，是多个国际医学协会的成员或研究员。Baynes博士在南非威特沃特斯兰德大学（University of the Witwatersrand）获得医学学位和哲学博士学位，并在约翰内斯堡医院（Johannesburg Hospital）血液科和肿瘤科完成医学培训。
- Roy D. Baynes has served as a member of Board since December 2024. Since July 2022, Dr. Baynes has served as Executive Vice President and Chief Medical Officer of Eikon Therapeutics, Inc. (Nasdaq: EIKN), a biotechnology company. Prior to Eikon Therapeutics, Inc., until April 2022, he served as Senior Vice President and Head of Global Clinical Development at Merck Research Laboratories, the research division of Merck and Co., Inc., commencing in December 2013, and as Chief Medical Officer of Merck and Co., Inc., a global healthcare company, commencing in July 2016. Prior to his roles at Merck and Co., Inc., Dr. Baynes served as Senior Vice President of Oncology, Inflammation and Respiratory Therapeutics at Gilead Sciences, Inc., a biopharmaceutical company, from January 2012 to December 2013. Prior to Gilead Sciences, Inc., Dr. Baynes held positions of increasing responsibility at Amgen Inc., a biotechnology company, including Vice President of Global Clinical Development and Therapeutic Area Head for Hematology/Oncology. Before joining Amgen Inc., Dr. Baynes was the Charles Martin Professor of Cancer Research at the Barbara Ann Karmanos Cancer Institute, a National Cancer Institute designated Comprehensive Cancer Center, at Wayne State University. Dr. Baynes has authored more than 150 publications and is a member or fellow of several international medical societies. Dr. Baynes has served on the Boards of Directors of Natera, Inc. (Nasdaq: NTRA), a genetic testing and diagnostics company, since July 2018; Travere Therapeutics Inc. (formerly known as Retrophin, Inc.) (Nasdaq: TVTX), a biopharmaceutical company, since July 2016; CatalYm GmbH, a privately held Germany based biotechnology company, since January 2024; Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company, since March 2025; and Adcendo ApS, a privately held Danish based antibody drug conjugate company, since February 2025. Previously, from September 2018 to December 2022, he served on the board of directors of Atara Biotherapeutics, Inc., a T cell immunotherapy company. Dr. Baynes received his medical degree and doctorate in philosophy from the University of the Witwatersrand in South Africa, and completed his medical training in the Department of Hematology and Oncology at Johannesburg Hospital.
- Tien Li Lee
-
Tien Li Lee，拥有超过20年的生物技术创新者和高管经验，曾整体参与多家生物制药公司的创立或推进。在创立我们公司之前，Dr. Lee于2013年加入上市的免疫疗法公司NantKwest，Inc.（纳斯达克：NK），并担任其首席战略官至2017年3月。在此之前，Lee博士于2011年至2013年担任先声药业业务发展总监，并于2007年至2011年担任Onkor Pharma，Inc.的联合创始人兼业务发展副总裁。他的经验包括免疫学、心血管、肿瘤学、神经学和传染病适应症的治疗。Lee博士于2019年3月至2023年8月期间担任Scilex Holding Company的董事。Lee博士还是多项生物医学和生物技术创新的发明人或共同发明人，获得许可或分配给多家公司进行开发，包括NantKwest，Inc.、先声药业、Cellics Therapeutics，Inc.和本公司。Lee博士在加州大学圣地亚哥分校获得医学博士学位，在加州大学伯克利分校获得分子生物学学士学位，他也是该校的校董和校友学者。Lee博士在加州大学洛杉矶分校接受了内科研究生培训，并在加州大学欧文分校接受了物理医学和康复方面的培训。
Tien Li Lee has served as Chief Executive Officer since March 2017. Dr. Lee has over 20 years of experience as a biotechnology innovator and executive who has been integrally involved with the founding or advancement of several biopharmaceutical companies. Prior to founding company, Dr. Lee joined NantKwest, Inc. (Nasdaq: NK), a publicly traded immunotherapy company, in 2013 and served as its Chief Strategy Officer until March 2017. Prior to this, Dr. Lee served as the Director of Business Development at Simcere Pharmaceutical Group from 2011 to 2013 and as the co founder and Vice President of Business Development of Onkor Pharma, Inc. from 2007 to 2011. His experience includes therapeutics for immunology, cardiovascular, oncology, neurology and infectious disease indications. Dr. Lee served as a director of Scilex Holding Company from March 2019 to August 2023. Dr. Lee is also an inventor or co inventor of multiple biomedical and biotechnology innovations, licensed or assigned to several companies for development including NantKwest, Inc., Simcere Pharmaceutical Group, Cellics Therapeutics, Inc. and company. Dr. Lee received his M.D. from the University of California, San Diego and his B.A. from the University of California, Berkeley in Molecular Biology where he was also a Regents and Alumni Scholar. Dr. Lee received post graduate training in Internal Medicine at University of California Los Angeles and Physical Medicine and Rehabilitation at University of California Irvine. - Tien Li Lee，拥有超过20年的生物技术创新者和高管经验，曾整体参与多家生物制药公司的创立或推进。在创立我们公司之前，Dr. Lee于2013年加入上市的免疫疗法公司NantKwest，Inc.（纳斯达克：NK），并担任其首席战略官至2017年3月。在此之前，Lee博士于2011年至2013年担任先声药业业务发展总监，并于2007年至2011年担任Onkor Pharma，Inc.的联合创始人兼业务发展副总裁。他的经验包括免疫学、心血管、肿瘤学、神经学和传染病适应症的治疗。Lee博士于2019年3月至2023年8月期间担任Scilex Holding Company的董事。Lee博士还是多项生物医学和生物技术创新的发明人或共同发明人，获得许可或分配给多家公司进行开发，包括NantKwest，Inc.、先声药业、Cellics Therapeutics，Inc.和本公司。Lee博士在加州大学圣地亚哥分校获得医学博士学位，在加州大学伯克利分校获得分子生物学学士学位，他也是该校的校董和校友学者。Lee博士在加州大学洛杉矶分校接受了内科研究生培训，并在加州大学欧文分校接受了物理医学和康复方面的培训。
- Tien Li Lee has served as Chief Executive Officer since March 2017. Dr. Lee has over 20 years of experience as a biotechnology innovator and executive who has been integrally involved with the founding or advancement of several biopharmaceutical companies. Prior to founding company, Dr. Lee joined NantKwest, Inc. (Nasdaq: NK), a publicly traded immunotherapy company, in 2013 and served as its Chief Strategy Officer until March 2017. Prior to this, Dr. Lee served as the Director of Business Development at Simcere Pharmaceutical Group from 2011 to 2013 and as the co founder and Vice President of Business Development of Onkor Pharma, Inc. from 2007 to 2011. His experience includes therapeutics for immunology, cardiovascular, oncology, neurology and infectious disease indications. Dr. Lee served as a director of Scilex Holding Company from March 2019 to August 2023. Dr. Lee is also an inventor or co inventor of multiple biomedical and biotechnology innovations, licensed or assigned to several companies for development including NantKwest, Inc., Simcere Pharmaceutical Group, Cellics Therapeutics, Inc. and company. Dr. Lee received his M.D. from the University of California, San Diego and his B.A. from the University of California, Berkeley in Molecular Biology where he was also a Regents and Alumni Scholar. Dr. Lee received post graduate training in Internal Medicine at University of California Los Angeles and Physical Medicine and Rehabilitation at University of California Irvine.
- Jeffrey Chi
-
Jeffrey Chi，是创投行业的资深人士，也是推动风险投资、创业&社会责任投资的坚定倡导者。池博士于2020年2月至2022年11月期间担任Vickers Vantage Corp. I董事会主席及首席执行官。Dr. Chi于2005年共同创立了Vickers Ventures Partners，并担任其副董事长以及董事会和投资委员会成员。2013年至2017年4月，池博士还担任新加坡风险投资和私募股权协会主席。从2001年到2005年，Dr. Chi最初担任Monitor Group的高级顾问，后来担任Pegasus Capital的执行董事。Dr. Chi还担任新加坡金融管理局顾问小组成员，此前曾担任SEEDS Capital（新加坡企业集团的投资部门）以及顾问小组ETLP（A的商业化部门*Star）和新加坡国立大学工业系统工程与管理系。Dr. Chi常驻上海，领导Vickers Venture在亚洲的投资，并投资于人工智能、教育、医疗保健/健康和金融服务（包括金融科技）技术公司。在管理风险投资基金之前，Dr. Chi为公共和私营部门的广泛客户管理咨询业务。Dr. Chi的运营背景包括在一家工程和建筑集团的管理团队工作，负责监督新加坡、马来西亚、台湾和印度尼西亚的运营。Dr. Chi还担任Vivance Pte Ltd（一家肾脏护理公司）、Jing-jin Electric Technologies Co.，Ltd.（SH：668280）和MatchMove Pay Pte. Ltd.的董事会成员。Dr. Chi获得了麻省理工学院系统工程博士学位、剑桥大学工程学硕士学位、麻省理工学院工程学硕士学位和剑桥大学工程学学士学位。他也是一名C.F.A.特许持有人，英语和普通话都很流利。
Jeffrey Chi has served as a member of Board since May 2019 and has served as Lead Independent Director since December 2024. Dr. Chi is a veteran in the venture capital industry and a strong advocate for the promotion of venture capital, entrepreneurship & socially responsible investing. Dr. Chi has served as the Chairman of the board of directors of Vickers Vantage Corp. I and its Chief Executive Officer from February 2020 to November 2022. Dr. Chi co founded Vickers Ventures Partners ("Vickers Ventures") in 2005, and served as its Vice Chairman and a member of its board of directors and Investment Committee until he transitioned into a senior consultant role in 2025. From 2013 to April 2017, Dr. Chi also served as the Chairman of the Singapore Venture Capital and Private Equity Association. From 2001 to 2005, Dr. Chi initially served as a Senior Consultant with the Monitor Group and later served as Executive Director with Pegasus Capital. Dr. Chi also sits on an advisory panel of the Monetary Authority of Singapore and previously sat on the board of SEEDS Capital (the investment arm of Enterprise Singapore) as well as on the advisory panels ETPL (the commercialization arm of A*Star) and the National University of Singapore Department of Industrial Systems Engineering and Management. Based out of Shanghai, Dr. Chi previously led Vickers Ventures' investments in Asia and has investments in artificial intelligence, education, healthcare/wellness and financial services (including fintech) technology companies. Prior to managing venture capital funds, Dr. Chi managed advisory engagements for a wide range of clients in both the public and private sectors. Dr. Chi's operational background includes working on the management team of an engineering and construction group where he oversaw operations in Singapore, Malaysia, Taiwan and Indonesia. Dr. Chi also serves as a member of the board of directors of Vivance Pte Ltd (a renal care company), Jing jin Electric Technologies Co., Ltd. (SH: 668280) and MatchMove Pay Pte. Ltd. Dr. Chi received his Ph.D. from the Massachusetts Institute of Technology in systems engineering, his M.A. from the University of Cambridge in engineering, his S.M. from the Massachusetts Institute of Technology in engineering and his B.A. from the University of Cambridge in engineering. He is also a C.F.A. charterholder and is fluent in English and Mandarin. - Jeffrey Chi，是创投行业的资深人士，也是推动风险投资、创业&社会责任投资的坚定倡导者。池博士于2020年2月至2022年11月期间担任Vickers Vantage Corp. I董事会主席及首席执行官。Dr. Chi于2005年共同创立了Vickers Ventures Partners，并担任其副董事长以及董事会和投资委员会成员。2013年至2017年4月，池博士还担任新加坡风险投资和私募股权协会主席。从2001年到2005年，Dr. Chi最初担任Monitor Group的高级顾问，后来担任Pegasus Capital的执行董事。Dr. Chi还担任新加坡金融管理局顾问小组成员，此前曾担任SEEDS Capital（新加坡企业集团的投资部门）以及顾问小组ETLP（A的商业化部门*Star）和新加坡国立大学工业系统工程与管理系。Dr. Chi常驻上海，领导Vickers Venture在亚洲的投资，并投资于人工智能、教育、医疗保健/健康和金融服务（包括金融科技）技术公司。在管理风险投资基金之前，Dr. Chi为公共和私营部门的广泛客户管理咨询业务。Dr. Chi的运营背景包括在一家工程和建筑集团的管理团队工作，负责监督新加坡、马来西亚、台湾和印度尼西亚的运营。Dr. Chi还担任Vivance Pte Ltd（一家肾脏护理公司）、Jing-jin Electric Technologies Co.，Ltd.（SH：668280）和MatchMove Pay Pte. Ltd.的董事会成员。Dr. Chi获得了麻省理工学院系统工程博士学位、剑桥大学工程学硕士学位、麻省理工学院工程学硕士学位和剑桥大学工程学学士学位。他也是一名C.F.A.特许持有人，英语和普通话都很流利。
- Jeffrey Chi has served as a member of Board since May 2019 and has served as Lead Independent Director since December 2024. Dr. Chi is a veteran in the venture capital industry and a strong advocate for the promotion of venture capital, entrepreneurship & socially responsible investing. Dr. Chi has served as the Chairman of the board of directors of Vickers Vantage Corp. I and its Chief Executive Officer from February 2020 to November 2022. Dr. Chi co founded Vickers Ventures Partners ("Vickers Ventures") in 2005, and served as its Vice Chairman and a member of its board of directors and Investment Committee until he transitioned into a senior consultant role in 2025. From 2013 to April 2017, Dr. Chi also served as the Chairman of the Singapore Venture Capital and Private Equity Association. From 2001 to 2005, Dr. Chi initially served as a Senior Consultant with the Monitor Group and later served as Executive Director with Pegasus Capital. Dr. Chi also sits on an advisory panel of the Monetary Authority of Singapore and previously sat on the board of SEEDS Capital (the investment arm of Enterprise Singapore) as well as on the advisory panels ETPL (the commercialization arm of A*Star) and the National University of Singapore Department of Industrial Systems Engineering and Management. Based out of Shanghai, Dr. Chi previously led Vickers Ventures' investments in Asia and has investments in artificial intelligence, education, healthcare/wellness and financial services (including fintech) technology companies. Prior to managing venture capital funds, Dr. Chi managed advisory engagements for a wide range of clients in both the public and private sectors. Dr. Chi's operational background includes working on the management team of an engineering and construction group where he oversaw operations in Singapore, Malaysia, Taiwan and Indonesia. Dr. Chi also serves as a member of the board of directors of Vivance Pte Ltd (a renal care company), Jing jin Electric Technologies Co., Ltd. (SH: 668280) and MatchMove Pay Pte. Ltd. Dr. Chi received his Ph.D. from the Massachusetts Institute of Technology in systems engineering, his M.A. from the University of Cambridge in engineering, his S.M. from the Massachusetts Institute of Technology in engineering and his B.A. from the University of Cambridge in engineering. He is also a C.F.A. charterholder and is fluent in English and Mandarin.
- Victor Tong, Jr.
-
Victor Tong，Jr.是一家投资公司Decheng Capital（Decheng）的董事总经理，自2012年成立以来，他一直在该公司工作，专注于对中国和美国的生物技术和医疗技术公司的投资。童先生在加入德诚集团之前，是生命科学投资公司Bay City Capital的负责人，也是摩根士丹利医疗保健投资银行部门的成员。童先生自2023年7月起担任CG Oncology，Inc.（纳斯达克：CGON）的董事会成员。他还在Cellares Corp.、Harton Therapeutics、Hummingbird Bioscience、LevitasBio、Nalu Medical、Take2、Watchmaker Genomics等多家私营生物技术和生物制药公司的董事会任职。Tong先生在加州大学伯克利分校获得分子和细胞生物学学士学位和工商管理学士学位。
Victor Tong, Jr. has served as a member of Board since May 2024. Mr. Tong is a Managing Director at Decheng Capital ("Decheng"), an investment firm, where he has worked since its inception in 2012 and focuses on investments in biotechnology and medical technology companies in China and the United States. Before joining Decheng, Mr. Tong was a Principal at Bay City Capital, a life sciences investment firm, and a member of the healthcare investment banking division at Morgan Stanley. Mr. Tong has served as a member of the board of directors of CG Oncology, Inc. (Nasdaq: CGON) since July 2023. He also serves on the board of directors of multiple privately held biotechnology and biopharmaceutical companies including Baylor Genetics, Cellares Corp., Harton Therapeutics, Hummingbird Bioscience, LevitasBio, Take2, and Watchmaker Genomics. Mr. Tong received his B.A. in Molecular and Cell Biology and his B.S. in Business Administration from the University of California, Berkeley. - Victor Tong，Jr.是一家投资公司Decheng Capital（Decheng）的董事总经理，自2012年成立以来，他一直在该公司工作，专注于对中国和美国的生物技术和医疗技术公司的投资。童先生在加入德诚集团之前，是生命科学投资公司Bay City Capital的负责人，也是摩根士丹利医疗保健投资银行部门的成员。童先生自2023年7月起担任CG Oncology，Inc.（纳斯达克：CGON）的董事会成员。他还在Cellares Corp.、Harton Therapeutics、Hummingbird Bioscience、LevitasBio、Nalu Medical、Take2、Watchmaker Genomics等多家私营生物技术和生物制药公司的董事会任职。Tong先生在加州大学伯克利分校获得分子和细胞生物学学士学位和工商管理学士学位。
- Victor Tong, Jr. has served as a member of Board since May 2024. Mr. Tong is a Managing Director at Decheng Capital ("Decheng"), an investment firm, where he has worked since its inception in 2012 and focuses on investments in biotechnology and medical technology companies in China and the United States. Before joining Decheng, Mr. Tong was a Principal at Bay City Capital, a life sciences investment firm, and a member of the healthcare investment banking division at Morgan Stanley. Mr. Tong has served as a member of the board of directors of CG Oncology, Inc. (Nasdaq: CGON) since July 2023. He also serves on the board of directors of multiple privately held biotechnology and biopharmaceutical companies including Baylor Genetics, Cellares Corp., Harton Therapeutics, Hummingbird Bioscience, LevitasBio, Take2, and Watchmaker Genomics. Mr. Tong received his B.A. in Molecular and Cell Biology and his B.S. in Business Administration from the University of California, Berkeley.
- Susan E. Graf
-
Susan E. Graf，自2021年5月起，Graf女士在全球生命科学交易公司Locust Walk Partners，LLC担任高级顾问和常驻企业家。2019年8月至2021年5月，她担任生物技术公司Akamara Therapeutics，Inc.的首席执行官。在加入Akamara Therapeutics，Inc.之前，她于2016年4月至2018年9月在生物制药公司Epizyme, Inc.担任首席商务官和首席财务官。在加入Epizyme, Inc.之前，Graf女士曾担任NPS制药公司企业发展和战略副总裁一职，之后于2015年被Shire收购。在她职业生涯的早期，格拉夫曾在罗氏公司担任过近18年的领导和行政职务。Graf女士目前担任后期临床生物制药公司CG Oncology，Inc.（Nasadq：CGON）和私营制药公司Kaléo，Inc.的董事会成员和审计委员会主席。2021年4月至2024年3月，她担任Finch Therapeutics公司董事会和审计委员会主席，该公司是一家上市的微生物组疗法公司。Graf女士获得了纽约大学斯特恩商学院的工商管理硕士学位和普渡大学的药学学士学位。
Susan E. Graf has served as a member of Board since November 2024. Since May 2021, Ms. Graf has served as a Senior Advisor and Entrepreneur in Residence at Locust Walk Partners, LLC, a global life science transaction firm. From August 2019 to May 2021, she served as the Chief Executive Officer of the biotechnology company, Akamara Therapeutics, Inc. Prior to Akamara Therapeutics, Inc., she was the Chief Business Officer at Epizyme, Inc., a biopharmaceutical company, from April 2016 to September 2018, where she also served as Principal Financial Officer from August 2017 to September 2018. Prior to Epizyme, Inc., Ms. Graf held the position of Vice President, Corporate Development and Strategy for NPS Pharma before it was acquired by Shire in 2015. Earlier in her career, Ms. Graf spent nearly 18 years at Roche in a number of leadership and executive positions. Ms. Graf currently serves on the boards of directors and as the chair of the audit committee of each of CG Oncology, Inc. (Nasdaq: CGON), a late stage clinical biopharmaceutical company, and Kaléo, Inc., a privately held pharmaceutical company. She also currently serves on the compensation committee of Kaléo, Inc. From April 2021 to March 2024, she chaired the board of directors and the audit committee of Finch Therapeutics, Inc., which was a publicly traded microbiome therapeutics company. Ms. Graf received her M.B.A. from the Stern School of Business at New York University and her B.Pharm. from Purdue University. - Susan E. Graf，自2021年5月起，Graf女士在全球生命科学交易公司Locust Walk Partners，LLC担任高级顾问和常驻企业家。2019年8月至2021年5月，她担任生物技术公司Akamara Therapeutics，Inc.的首席执行官。在加入Akamara Therapeutics，Inc.之前，她于2016年4月至2018年9月在生物制药公司Epizyme, Inc.担任首席商务官和首席财务官。在加入Epizyme, Inc.之前，Graf女士曾担任NPS制药公司企业发展和战略副总裁一职，之后于2015年被Shire收购。在她职业生涯的早期，格拉夫曾在罗氏公司担任过近18年的领导和行政职务。Graf女士目前担任后期临床生物制药公司CG Oncology，Inc.（Nasadq：CGON）和私营制药公司Kaléo，Inc.的董事会成员和审计委员会主席。2021年4月至2024年3月，她担任Finch Therapeutics公司董事会和审计委员会主席，该公司是一家上市的微生物组疗法公司。Graf女士获得了纽约大学斯特恩商学院的工商管理硕士学位和普渡大学的药学学士学位。
- Susan E. Graf has served as a member of Board since November 2024. Since May 2021, Ms. Graf has served as a Senior Advisor and Entrepreneur in Residence at Locust Walk Partners, LLC, a global life science transaction firm. From August 2019 to May 2021, she served as the Chief Executive Officer of the biotechnology company, Akamara Therapeutics, Inc. Prior to Akamara Therapeutics, Inc., she was the Chief Business Officer at Epizyme, Inc., a biopharmaceutical company, from April 2016 to September 2018, where she also served as Principal Financial Officer from August 2017 to September 2018. Prior to Epizyme, Inc., Ms. Graf held the position of Vice President, Corporate Development and Strategy for NPS Pharma before it was acquired by Shire in 2015. Earlier in her career, Ms. Graf spent nearly 18 years at Roche in a number of leadership and executive positions. Ms. Graf currently serves on the boards of directors and as the chair of the audit committee of each of CG Oncology, Inc. (Nasdaq: CGON), a late stage clinical biopharmaceutical company, and Kaléo, Inc., a privately held pharmaceutical company. She also currently serves on the compensation committee of Kaléo, Inc. From April 2021 to March 2024, she chaired the board of directors and the audit committee of Finch Therapeutics, Inc., which was a publicly traded microbiome therapeutics company. Ms. Graf received her M.B.A. from the Stern School of Business at New York University and her B.Pharm. from Purdue University.
高管简历
中英对照 | 中文 | 英文- Tien Li Lee
Tien Li Lee，拥有超过20年的生物技术创新者和高管经验，曾整体参与多家生物制药公司的创立或推进。在创立我们公司之前，Dr. Lee于2013年加入上市的免疫疗法公司NantKwest，Inc.（纳斯达克：NK），并担任其首席战略官至2017年3月。在此之前，Lee博士于2011年至2013年担任先声药业业务发展总监，并于2007年至2011年担任Onkor Pharma，Inc.的联合创始人兼业务发展副总裁。他的经验包括免疫学、心血管、肿瘤学、神经学和传染病适应症的治疗。Lee博士于2019年3月至2023年8月期间担任Scilex Holding Company的董事。Lee博士还是多项生物医学和生物技术创新的发明人或共同发明人，获得许可或分配给多家公司进行开发，包括NantKwest，Inc.、先声药业、Cellics Therapeutics，Inc.和本公司。Lee博士在加州大学圣地亚哥分校获得医学博士学位，在加州大学伯克利分校获得分子生物学学士学位，他也是该校的校董和校友学者。Lee博士在加州大学洛杉矶分校接受了内科研究生培训，并在加州大学欧文分校接受了物理医学和康复方面的培训。
Tien Li Lee has served as Chief Executive Officer since March 2017. Dr. Lee has over 20 years of experience as a biotechnology innovator and executive who has been integrally involved with the founding or advancement of several biopharmaceutical companies. Prior to founding company, Dr. Lee joined NantKwest, Inc. (Nasdaq: NK), a publicly traded immunotherapy company, in 2013 and served as its Chief Strategy Officer until March 2017. Prior to this, Dr. Lee served as the Director of Business Development at Simcere Pharmaceutical Group from 2011 to 2013 and as the co founder and Vice President of Business Development of Onkor Pharma, Inc. from 2007 to 2011. His experience includes therapeutics for immunology, cardiovascular, oncology, neurology and infectious disease indications. Dr. Lee served as a director of Scilex Holding Company from March 2019 to August 2023. Dr. Lee is also an inventor or co inventor of multiple biomedical and biotechnology innovations, licensed or assigned to several companies for development including NantKwest, Inc., Simcere Pharmaceutical Group, Cellics Therapeutics, Inc. and company. Dr. Lee received his M.D. from the University of California, San Diego and his B.A. from the University of California, Berkeley in Molecular Biology where he was also a Regents and Alumni Scholar. Dr. Lee received post graduate training in Internal Medicine at University of California Los Angeles and Physical Medicine and Rehabilitation at University of California Irvine.- Tien Li Lee，拥有超过20年的生物技术创新者和高管经验，曾整体参与多家生物制药公司的创立或推进。在创立我们公司之前，Dr. Lee于2013年加入上市的免疫疗法公司NantKwest，Inc.（纳斯达克：NK），并担任其首席战略官至2017年3月。在此之前，Lee博士于2011年至2013年担任先声药业业务发展总监，并于2007年至2011年担任Onkor Pharma，Inc.的联合创始人兼业务发展副总裁。他的经验包括免疫学、心血管、肿瘤学、神经学和传染病适应症的治疗。Lee博士于2019年3月至2023年8月期间担任Scilex Holding Company的董事。Lee博士还是多项生物医学和生物技术创新的发明人或共同发明人，获得许可或分配给多家公司进行开发，包括NantKwest，Inc.、先声药业、Cellics Therapeutics，Inc.和本公司。Lee博士在加州大学圣地亚哥分校获得医学博士学位，在加州大学伯克利分校获得分子生物学学士学位，他也是该校的校董和校友学者。Lee博士在加州大学洛杉矶分校接受了内科研究生培训，并在加州大学欧文分校接受了物理医学和康复方面的培训。
- Tien Li Lee has served as Chief Executive Officer since March 2017. Dr. Lee has over 20 years of experience as a biotechnology innovator and executive who has been integrally involved with the founding or advancement of several biopharmaceutical companies. Prior to founding company, Dr. Lee joined NantKwest, Inc. (Nasdaq: NK), a publicly traded immunotherapy company, in 2013 and served as its Chief Strategy Officer until March 2017. Prior to this, Dr. Lee served as the Director of Business Development at Simcere Pharmaceutical Group from 2011 to 2013 and as the co founder and Vice President of Business Development of Onkor Pharma, Inc. from 2007 to 2011. His experience includes therapeutics for immunology, cardiovascular, oncology, neurology and infectious disease indications. Dr. Lee served as a director of Scilex Holding Company from March 2019 to August 2023. Dr. Lee is also an inventor or co inventor of multiple biomedical and biotechnology innovations, licensed or assigned to several companies for development including NantKwest, Inc., Simcere Pharmaceutical Group, Cellics Therapeutics, Inc. and company. Dr. Lee received his M.D. from the University of California, San Diego and his B.A. from the University of California, Berkeley in Molecular Biology where he was also a Regents and Alumni Scholar. Dr. Lee received post graduate training in Internal Medicine at University of California Los Angeles and Physical Medicine and Rehabilitation at University of California Irvine.
- Manasi Jaiman
Manasi Jaiman，在加入我们之前，从2022年10月到2024年3月，Jaiman博士在Vertex Pharmaceuticals Incorporated（纳斯达克：VRTX）担任临床开发和平台主管副总裁，从2020年7月到2023年7月，她在生物技术公司ViaCyte，Inc.（纳斯达克：VCYT）担任过各种职务，包括担任其首席医疗官和临床开发副总裁，在那里她开发了细胞治疗的新方法。在此之前，她曾在CRO Covance/LabCorp担任高级医疗总监和医疗总监。此前，2014年7月至2020年9月，她在哈佛医学院和麻省总医院担任主治医师，负责儿科内分泌患者的临床护理，包括糖尿病、代谢性疾病、肥胖症和普拉德-威利综合征患者。她还担任了马萨诸塞州总医院开发仿生胰腺的多项试验的共同研究者。Jaiman博士在南卡罗来纳医科大学获得医学博士学位，在杜兰大学公共卫生和热带医学学院获得医学硕士学位，在南卡罗来纳大学荣誉学院获得心理学学士学位。她在达特茅斯-希区柯克医疗中心完成了儿科住院医师实习，并在麻省总医院完成了专注于1型糖尿病研究的儿科内分泌学研究金。
Manasi Jaiman has served as Chief Medical Officer since September 2024. Prior to joining Aardvark Therapeutics, Inc., from October 2022 to March 2024, Dr. Jaiman was Vice President, Clinical Development and Platform Lead at Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX), and from July 2020 to July 2023, she served in various roles at ViaCyte, Inc. (Nasdaq: VCYT), a biotechnology company, including as its Chief Medical Officer and Vice President of Clinical Development, where she developed novel approaches in cell therapy. Prior to that, she served as Senior Medical Director and Medical Director at Covance/LabCorp, a CRO. Previously, from July 2014 to September 2020, she was an attending physician at Harvard Medical School and Massachusetts General Hospital, where she was responsible for the clinical care of pediatric endocrinology patients, including those with diabetes, metabolic disease, obesity and Prader Willi Syndrome. She also served as a co investigator for several trials developing the bionic pancreas at Massachusetts General Hospital. Dr. Jaiman received her M.D. from Medical University of South Carolina, her M.P.H. from Tulane University School of Public Health and Tropical Medicine and her B.S. in Psychology from the University of South Carolina, Honors College. She completed her pediatric residency at Dartmouth Hitchcock Medical Center and her pediatric endocrinology fellowship, which focused on type 1 diabetes research, at Massachusetts General Hospital.- Manasi Jaiman，在加入我们之前，从2022年10月到2024年3月，Jaiman博士在Vertex Pharmaceuticals Incorporated（纳斯达克：VRTX）担任临床开发和平台主管副总裁，从2020年7月到2023年7月，她在生物技术公司ViaCyte，Inc.（纳斯达克：VCYT）担任过各种职务，包括担任其首席医疗官和临床开发副总裁，在那里她开发了细胞治疗的新方法。在此之前，她曾在CRO Covance/LabCorp担任高级医疗总监和医疗总监。此前，2014年7月至2020年9月，她在哈佛医学院和麻省总医院担任主治医师，负责儿科内分泌患者的临床护理，包括糖尿病、代谢性疾病、肥胖症和普拉德-威利综合征患者。她还担任了马萨诸塞州总医院开发仿生胰腺的多项试验的共同研究者。Jaiman博士在南卡罗来纳医科大学获得医学博士学位，在杜兰大学公共卫生和热带医学学院获得医学硕士学位，在南卡罗来纳大学荣誉学院获得心理学学士学位。她在达特茅斯-希区柯克医疗中心完成了儿科住院医师实习，并在麻省总医院完成了专注于1型糖尿病研究的儿科内分泌学研究金。
- Manasi Jaiman has served as Chief Medical Officer since September 2024. Prior to joining Aardvark Therapeutics, Inc., from October 2022 to March 2024, Dr. Jaiman was Vice President, Clinical Development and Platform Lead at Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX), and from July 2020 to July 2023, she served in various roles at ViaCyte, Inc. (Nasdaq: VCYT), a biotechnology company, including as its Chief Medical Officer and Vice President of Clinical Development, where she developed novel approaches in cell therapy. Prior to that, she served as Senior Medical Director and Medical Director at Covance/LabCorp, a CRO. Previously, from July 2014 to September 2020, she was an attending physician at Harvard Medical School and Massachusetts General Hospital, where she was responsible for the clinical care of pediatric endocrinology patients, including those with diabetes, metabolic disease, obesity and Prader Willi Syndrome. She also served as a co investigator for several trials developing the bionic pancreas at Massachusetts General Hospital. Dr. Jaiman received her M.D. from Medical University of South Carolina, her M.P.H. from Tulane University School of Public Health and Tropical Medicine and her B.S. in Psychology from the University of South Carolina, Honors College. She completed her pediatric residency at Dartmouth Hitchcock Medical Center and her pediatric endocrinology fellowship, which focused on type 1 diabetes research, at Massachusetts General Hospital.
- Nelson Sun
Nelson Sun，在财务管理、业务运营、公司战略方面拥有20多年的经验，曾在私募股权公司担任多个领导职务。在加入我们之前，孙先生曾于2011年至2019年担任Dubilier & Company的运营合伙人，负责评估表现不佳的资产和战略收购机会，同时为投资组合公司提供跨越业务运营、财务规划和战略退出的执行级别监督。从2005年到2011年，孙先生在Valor Equity Partners担任副总裁，负责并购、投资组合管理，以及为投资组合公司提供高管级别的监督，包括运营领导、公司战略、财务管理和运营可扩展性。在其职业生涯早期，他曾在Dubilier & Company从事财务估值分析和交易支持工作，在National Electronics Warranty从事产品管理工作，并在RevBox.com从事业务发展工作。孙先生在沃顿商学院获得金融硕士学位，在宾夕法尼亚大学文理学院获得国际研究硕士学位，在加州大学圣地亚哥分校获得文学/写作学士学位。
Nelson Sun has served as Chief Financial Officer since June 2019 and additionally as Chief Operating Officer since February 2026. Mr. Sun has more than 20 years' experience in financial management, business operations, and corporate strategy, with various leadership roles at private equity firms. Prior to joining Aardvark Therapeutics, Inc., Mr. Sun served as an Operating Partner at Dubilier & Company from 2011 to 2019, where he assessed underperforming assets and strategic acquisition opportunities, alongside providing executive level oversight to portfolio companies spanning business operations, financial planning, and strategic exits. From 2005 to 2011, Mr. Sun served as a Vice President at Valor Equity Partners, where he worked on mergers and acquisitions, portfolio management, as well as provided executive level oversight to portfolio companies including operations leadership, corporate strategy, financial management, and operational scalability. Earlier in his career, he worked in financial valuation analysis and transaction support at Dubilier & Company, in product management at National Electronics Warranty, and in business development at Revbox.com. Mr. Sun received his M.B.A. in Finance from The Wharton School, his M.A. in International Studies from the School of Arts and Sciences at the University of Pennsylvania and his B.A. in Literature/Writing from the University of California, San Diego.- Nelson Sun，在财务管理、业务运营、公司战略方面拥有20多年的经验，曾在私募股权公司担任多个领导职务。在加入我们之前，孙先生曾于2011年至2019年担任Dubilier & Company的运营合伙人，负责评估表现不佳的资产和战略收购机会，同时为投资组合公司提供跨越业务运营、财务规划和战略退出的执行级别监督。从2005年到2011年，孙先生在Valor Equity Partners担任副总裁，负责并购、投资组合管理，以及为投资组合公司提供高管级别的监督，包括运营领导、公司战略、财务管理和运营可扩展性。在其职业生涯早期，他曾在Dubilier & Company从事财务估值分析和交易支持工作，在National Electronics Warranty从事产品管理工作，并在RevBox.com从事业务发展工作。孙先生在沃顿商学院获得金融硕士学位，在宾夕法尼亚大学文理学院获得国际研究硕士学位，在加州大学圣地亚哥分校获得文学/写作学士学位。
- Nelson Sun has served as Chief Financial Officer since June 2019 and additionally as Chief Operating Officer since February 2026. Mr. Sun has more than 20 years' experience in financial management, business operations, and corporate strategy, with various leadership roles at private equity firms. Prior to joining Aardvark Therapeutics, Inc., Mr. Sun served as an Operating Partner at Dubilier & Company from 2011 to 2019, where he assessed underperforming assets and strategic acquisition opportunities, alongside providing executive level oversight to portfolio companies spanning business operations, financial planning, and strategic exits. From 2005 to 2011, Mr. Sun served as a Vice President at Valor Equity Partners, where he worked on mergers and acquisitions, portfolio management, as well as provided executive level oversight to portfolio companies including operations leadership, corporate strategy, financial management, and operational scalability. Earlier in his career, he worked in financial valuation analysis and transaction support at Dubilier & Company, in product management at National Electronics Warranty, and in business development at Revbox.com. Mr. Sun received his M.B.A. in Finance from The Wharton School, his M.A. in International Studies from the School of Arts and Sciences at the University of Pennsylvania and his B.A. in Literature/Writing from the University of California, San Diego.